Condition

Uterine cancer

Clinical trials and treatment information for Uterine cancer

3.5M
People Affected
200
Active Trials
863K
New Cases/Year
98K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Hysterectomy (Surgical Resection)
90% Effectiveness• 95% Confidence• 45% Safety• 41 trials• 1M participants
HIGH EvidenceExcellent ValueDose: Surgical procedure
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe

Time to Effect

Immediate

Duration

One-time procedure, 4-8 weeks recovery

Response Rate

%

Remission Rate

85%

Common Side Effects:

Pain: 90%
Infection: 10%
Bleeding: 5%
Damage to adjacent organs: 2%
Deep vein thrombosis/Pulmonary embolism: 1%
Lymphedema (with lymphadenectomy): 20%

Annual Cost of Care

Drug Cost

$500

Monitoring

$10,000

Side Effects

$1,500

Total Annual

$25,000

Cost-Effectiveness

EXCELLENT

QALYs Gained

3.5

Cost per Remission

$29,412

Treatment Outcomes
Primary Outcomes
5-Year Overall Survival Rate60-75% (estimated for comparable stage/grade without definitive surgical treatment)
+15% (+10.5% (e.g., from 70% to 80.5%))
5-Year Disease-Free Survival Rate50-65% (estimated for comparable stage/grade without definitive surgical treatment)
+20% (+12% (e.g., from 60% to 72%))
5-Year Risk of Local/Regional Recurrence15-25% (estimated for comparable stage/grade without definitive surgical treatment)
-60% (-9-15% reduction (e.g., from 20% to 8%))
Secondary Benefits
Frequency of Abnormal Uterine BleedingDaily to weekly episodes of spotting to heavy bleeding
-100% (Complete cessation of bleeding)
Pelvic Pain Score (e.g., VAS 0-10)Moderate pain (e.g., 6/10 VAS)
-83.3% (-5 points on VAS (e.g., from 6 to 1))
Health-Related Quality of Life (e.g., EORTC QLQ-C30 Global Health Status)Impaired (e.g., 50/100 points)
+20% (+10 points on EORTC QLQ-C30 GHS (e.g., from 50 to 60))
Common Side Effects
Pain
+90%
Infection
+10%
Bleeding
+5%
2
Lenvatinib + Pembrolizumab
65% Effectiveness• 90% Confidence• 35% Safety• 15 trials• 5K participants
HIGH EvidencePoor ValueDose: Lenvatinib 20mg daily, Pembrolizumab 200mg IV every 3 weeks or 400mg IV every 6 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe

Time to Effect

1-3 months

Duration

Until progression or unacceptable toxicity

Response Rate

38%

Remission Rate

5%

Number Needed to Treat (NNT)

6

Number Needed to Harm (NNH)

3

Common Side Effects:

Hypertension: 70%
Fatigue: 65%
Musculoskeletal pain: 50%
Diarrhea: 45%
Hypothyroidism: 40%
Palmar-plantar erythrodysesthesia: 35%
Proteinuria: 30%
Immune-related adverse events: 20%

Annual Cost of Care

Drug Cost

$300,000

Monitoring

$15,000

Side Effects

$10,000

Total Annual

$325,000

Cost-Effectiveness

POOR

QALYs Gained

0.82

ICER

$195,000/QALY

Cost per Remission

$6,500,000

Cost per Responder

$855,263

Treatment Outcomes
Primary Outcomes
Median Progression-Free Survival3.8 months (typical with chemotherapy alone)
+89.5% (+3.4 months)
Median Overall Survival11.4 months (typical with chemotherapy alone)
+60.5% (+6.9 months)
Tumor Size Reduction (Sum of Target Lesion Diameters)100 mm (representative sum of diameters in responders)
-40% (-40 mm)
Secondary Benefits
Quality of Life (FACT-En Total Score)110 points (on a 0-144 scale; lower score indicates worse QoL)
+7.3% (+8 points)
Fatigue (FACIT-F Total Score)30 points (on a 0-52 scale; lower score indicates more fatigue)
+16.7% (+5 points)
Common Side Effects
Hypertension
+70%
Fatigue
+65%
Musculoskeletal pain
+50%

Clinical Trial Phases:

Phase 3Phase 4
3
Pembrolizumab (monotherapy)
60% Effectiveness• 90% Confidence• 40% Safety• 36 trials• 8K participants
HIGH EvidenceModerate ValueDose: 200mg IV every 3 weeks or 400mg IV every 6 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe

Time to Effect

1-3 months

Duration

Until progression or unacceptable toxicity

Response Rate

40%

Remission Rate

10%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

7

Common Side Effects:

Fatigue: 40%
Musculoskeletal pain: 25%
Diarrhea: 25%
Rash: 20%
Immune-related adverse events (colitis, hepatitis, pneumonitis, endocrinopathies): 15%

Annual Cost of Care

Drug Cost

$150,000

Monitoring

$10,000

Side Effects

$5,000

Total Annual

$165,000

Cost-Effectiveness

MODERATE

QALYs Gained

1.14

ICER

$104,000/QALY

Cost per Remission

$1,650,000

Cost per Responder

$412,500

Treatment Outcomes
Primary Outcomes
Sum of Diameters of Target Lesions (RECIST 1.1)100 mm
-35% (-35 mm)
Cancer-Related Pain Severity (NRS)NRS score: 6/10
-33.3% (-2 points)
Cancer-Related Fatigue Severity (FACT-F)FACT-F score: 20/52
+15% (+3 points)
Secondary Benefits
Global Health Status (EORTC QLQ-C30)EORTC QLQ-C30 GHS score: 50/100
+10% (+5 points)
Physical Functioning Score (EORTC QLQ-C30)EORTC QLQ-C30 PF score: 60/100
+8.3% (+5 points)
CA-125 Tumor Marker Level250 U/mL
-25% (-62.5 U/mL)
Common Side Effects
Fatigue
+40%
Musculoskeletal pain
+25%
Diarrhea
+25%

Clinical Trial Phases:

Phase 3Phase 4
4
Carboplatin + Paclitaxel (Adjuvant/Palliative Chemotherapy)
55% Effectiveness• 90% Confidence• 25% Safety• 200 trials• 30K participants
HIGH EvidenceModerate ValueDose: Carboplatin AUC 5-6, Paclitaxel 175 mg/m2 IV every 3 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

2-4 cycles (6-12 weeks)

Duration

3-6 cycles (3-6 months)

Response Rate

50%

Remission Rate

25%

Number Needed to Treat (NNT)

12

Number Needed to Harm (NNH)

4

Common Side Effects:

Myelosuppression (Neutropenia): 85%
Peripheral neuropathy: 60%
Alopecia: 90%
Nausea/Vomiting: 70%
Fatigue: 85%
Hypersensitivity reaction: 15%

Annual Cost of Care

Drug Cost

$10,000

Monitoring

$20,000

Side Effects

$15,000

Total Annual

$45,000

Cost-Effectiveness

MODERATE

QALYs Gained

1

ICER

$140,000/QALY

Cost per Remission

$180,000

Cost per Responder

$90,000

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+50%
Remission Rate
+25%
Common Side Effects
Myelosuppression (Neutropenia)
+85%
Peripheral neuropathy
+60%
Alopecia
+90%

Clinical Trial Phases:

Phase 3Phase 4
5
External Beam Radiation Therapy (EBRT)
45% Effectiveness• 85% Confidence• 25% Safety• 118 trials• 25K participants
HIGH EvidenceModerate ValueDose: 45-50.4 Gy in 1.8-2 Gy fractions
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Effects accrue during 4-6 week treatment

Duration

4-6 weeks (daily sessions)

Response Rate

%

Remission Rate

%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

15

Common Side Effects:

Fatigue: 70%
Diarrhea: 40%
Proctitis: 30%
Cystitis: 20%
Skin irritation: 60%
Vaginal stenosis (long-term): 30%

Annual Cost of Care

Drug Cost

$0

Monitoring

$25,000

Side Effects

$5,000

Total Annual

$30,000

Cost-Effectiveness

MODERATE

QALYs Gained

0.3

ICER

$110,000/QALY

Treatment Outcomes
Primary Outcomes
Pelvic Recurrence Rate at 5 years20% (for high-risk endometrial cancer without adjuvant therapy)
-50% (-10 percentage points)
5-Year Overall Survival Rate70% (for high-risk early-stage uterine cancer without adjuvant EBRT)
+10% (+7 percentage points)
Local Control Rate at 3 years50% (for locally advanced/recurrent uterine cancer without EBRT)
+40% (+20 percentage points)
Secondary Benefits
EORTC QLQ-C30 Global Health Status (0-100)60/100
+10% (+6 points)
Pain Intensity (NRS 0-10)6/10
-50% (-3 points)
ECOG Performance Status (0-5 scale)2/5
-50% (-1 point)
Common Side Effects
Fatigue
+70%
Diarrhea
+40%
Proctitis
+30%
6
Vaginal Brachytherapy
40% Effectiveness• 80% Confidence• 50% Safety• 64 trials• 10K participants
HIGH EvidenceGood ValueDose: 21 Gy in 3 fractions or 30 Gy in 5 fractions
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe

Time to Effect

Treatment course over 1-2 weeks

Duration

3-5 fractions over 1-2 weeks

Response Rate

%

Remission Rate

%

Number Needed to Treat (NNT)

7

Number Needed to Harm (NNH)

25

Common Side Effects:

Vaginal dryness: 40%
Vaginal stenosis: 30%
Mild bladder irritation: 15%
Mild bowel irritation: 10%

Annual Cost of Care

Drug Cost

$0

Monitoring

$10,000

Side Effects

$1,000

Total Annual

$11,000

Cost-Effectiveness

GOOD

QALYs Gained

0.2

ICER

$70,000/QALY

Treatment Outcomes
Primary Outcomes
Vaginal Recurrence Rate (5-year)7.5% (expected without adjuvant brachytherapy in intermediate-high risk endometrial cancer after hysterectomy)
-80% (-6 percentage points)
Overall Recurrence Rate (5-year)20% (expected in intermediate-high risk endometrial cancer without adjuvant therapy)
-25% (-5 percentage points)
Disease-Free Survival Rate (5-year)75% (expected in intermediate-high risk endometrial cancer without adjuvant therapy)
+6.67% (+5 percentage points)
Secondary Benefits
Emotional Functioning Score (EORTC QLQ-C30, 0-100, higher is better)60/100 (post-diagnosis/surgery)
+25% (+15 points)
Future Uncertainty Scale (EORTC QLQ-EN24, 0-100, lower is better)50/100 (moderate uncertainty post-diagnosis)
-30% (-15 points)
Common Side Effects
Vaginal dryness
+40%
Vaginal stenosis
+30%
Mild bladder irritation
+15%
7
Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy)
35% Effectiveness• 75% Confidence• 60% Safety• 40 trials• 5K participants
MODERATE EvidenceExcellent ValueDose: MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

1-3 months

Duration

6-12 months or longer for recurrent disease

Response Rate

40%

Remission Rate

25%

Common Side Effects:

Weight gain: 40%
Fluid retention: 30%
Hot flashes: 25%
Mood changes: 15%
Increased risk of venous thromboembolism: 7%

Annual Cost of Care

Drug Cost

$300

Monitoring

$2,000

Side Effects

$200

Total Annual

$2,500

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.2

ICER

$12,500/QALY

Cost per Remission

$10,000

Cost per Responder

$6,250

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+35%
Response Rate
+40%
Remission Rate
+25%
Common Side Effects
Weight gain
+40%
Fluid retention
+30%
Hot flashes
+25%